Want to see HK:1672 full AI Analyst Report?
1672 Stock Chart & Stats
HK$10.10
-HK$0.23(-2.51%)
At close: 4:00 PM EDT
HK$10.10
-HK$0.23(-2.51%)
Day’s Range― - ―
52-Week RangeHK$7.95 - HK$19.86
Previous CloseN/A
Volume1.64M
Average Volume (3M)2.28M
Market Cap
HK$9.42B
Enterprise ValueHK$8.36K
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$5.16M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 30, 2027EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,057,769,000
10 Day Avg. Volume3,395,338
30 Day Avg. Volume2,279,323
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.96
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$14.20Price Target Upside40.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)HK$11.87M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces solvency pressure and leaves more balance-sheet flexibility than a highly indebted structure would provide. This can help preserve strategic options for funding development or absorbing operating volatility, despite current losses.
In-House R&D And PipelineIn-house research capabilities and an advancing clinical pipeline provide a foundation for developing future products rather than relying only on current commercial medicines. If candidates progress successfully, this platform could support longer-term product renewal and growth.
Multiple Monetization ChannelsThe business model includes several potential sources of pharmaceutical income, including commercial sales and partnership-based milestones or royalties. This creates more than one route to monetization as products advance, although realized value depends on execution and product development.
Bears Say
Severe Revenue ContractionThe sharp multi-year revenue decline indicates substantial deterioration in the current commercial base, with 2025 still below 2024. A much smaller revenue run-rate reduces operating leverage, limits internal funding capacity, and raises the importance of pipeline execution.
Persistent UnprofitabilityPersistent losses, culminating in negative gross profit in 2025, show that the present revenue base is insufficient to cover the cost structure. Unless profitability improves materially, ongoing deficits may continue eroding equity and constrain investment in future products.
Accelerating Cash BurnNegative operating and free cash flow in every year, alongside a sharp step-up in operating burn since 2023, shows the company is not self-funding operations. Continued cash consumption can increase dependence on financing and reduce flexibility for pipeline development.
Ascletis Pharma, Inc. News
1672 FAQ
What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$7.95 and its highest was HK$19.86 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Ascletis Pharma, Inc.’s market cap is HK$9.42B.
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 191 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.359 earnings per share for the quarter, missing the consensus estimate of -HK$0.234 by -HK$0.125.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Undervalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 1,057,769,000 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.359 in its last earnings report, missing expectations of -HK$0.234. Following the earnings report the stock price went down -0.792%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascletis Pharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
29.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ascletis Pharma, Inc.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
1672 Stock 12 Month Forecast
Average Price Target
HK$14.20
▲(40.54% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―